0001558370-25-010185 | 10-Q | XBRL Viewer | Harmony Biosciences Holdings INC

LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS (Details) - USD ($) $ in Thousands	1 Months Ended							3 Months Ended	6 Months Ended	12 Months Ended
	Mar. 31, 2023	Oct. 31, 2022	Mar. 31, 2022	Jan. 31, 2021	Oct. 31, 2020	Nov. 30, 2019	Aug. 31, 2019	Jun. 30, 2025	Jun. 30, 2025	Dec. 31, 2024	Apr. 30, 2024	Jul. 31, 2022	Aug. 31, 2021	Feb. 28, 2019
License Agreements and Asset Purchase Agreements
License agreement, milestone payment due							$ 77,000							$ 50,000
Licensing agreement milestone fees							2,000
License agreement milestone payments paid				$ 100,000	$ 2,000	$ 75,000	2,000
License agreement, additional milestone payment due							$ 102,000
Final payment paid			$ 40,000
Amount of Aggregate Net Sales Attaining			$ 500,000
License agreement, upfront non-refundable licensing fees paid		$ 30,000
License agreement, maximum additional milestone payment due												$ 155,000
Payment of upfront license fee								$ 15,000	$ 15,000	$ 25,500
Amount of fee payable upon achieving development and regulatory milestones											$ 127,500
Amount of fees payable upon achieving sale-based milestones											$ 240,000
Payment related to achievement of preclinical milestone	$ 750									$ 1,000
Payment for intellectual property upon developmental milestones													$ 19,000
Payment for intellectual property upon regulatory milestones													44,000
Payment for intellectual property upon sales milestones													$ 110,000

Label	Element	Value
Payment of Upfront Fee, Investing Activities	hrmy_PaymentOfUpfrontFeeInvestingActivities	$ 15,000,000
Payment of Upfront Fee, Investing Activities	hrmy_PaymentOfUpfrontFeeInvestingActivities	$ 25,500,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Remaining Contractual Terms	hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms	4 years 3 months 18 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Remaining Contractual Terms	hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms	3 years 9 months 18 days
Stock Issued During Period, Value, Stock Options and Restricted Stock Units Exercised	hrmy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercised	$ 4,462,000
Stock Issued During Period, Value, Stock Options and Restricted Stock Units Exercised	hrmy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercised	4,462,000
Stock Issued During Period, Value, Stock Options and Restricted Stock Units Exercised	hrmy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercised	420,000
Stock Issued During Period, Value, Stock Options and Restricted Stock Units Exercised	hrmy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercised	420,000
Accrued Research And Development Current	hrmy_AccruedResearchAndDevelopmentCurrent	7,590,000
Accrued Research And Development Current	hrmy_AccruedResearchAndDevelopmentCurrent	$ 9,014,000
Non Current Investment Maturity Term	hrmy_NonCurrentInvestmentMaturityTerm	1 year
Non Current Investment Maturity Term	hrmy_NonCurrentInvestmentMaturityTerm	2 years
General and Administrative Expense Excluding Share-based Compensation, Depreciation and Amortization	hrmy_GeneralAndAdministrativeExpenseExcludingShareBasedCompensationDepreciationAndAmortization	$ 20,334,000
General and Administrative Expense Excluding Share-based Compensation, Depreciation and Amortization	hrmy_GeneralAndAdministrativeExpenseExcludingShareBasedCompensationDepreciationAndAmortization	13,996,000
General and Administrative Expense Excluding Share-based Compensation, Depreciation and Amortization	hrmy_GeneralAndAdministrativeExpenseExcludingShareBasedCompensationDepreciationAndAmortization	38,212,000
General and Administrative Expense Excluding Share-based Compensation, Depreciation and Amortization	hrmy_GeneralAndAdministrativeExpenseExcludingShareBasedCompensationDepreciationAndAmortization	26,486,000
Accrued Liabilities, other than Accrued Compensation, Current	hrmy_AccruedLiabilitiesOtherThanAccruedCompensationCurrent	118,293,000
Accrued Liabilities, other than Accrued Compensation, Current	hrmy_AccruedLiabilitiesOtherThanAccruedCompensationCurrent	$ 120,640,000
Stock Issued During Period, Shares, Stock Options and Restricted Stock Units Exercised	hrmy_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsExercised	392,982
Stock Issued During Period, Shares, Stock Options and Restricted Stock Units Exercised	hrmy_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsExercised	64,690
Share-based Compensation Arrangement by Share-based Payment Award, Discount	hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscount	$ 65,000
Share-based Compensation Arrangement by Share-based Payment Award, Discount	hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscount	78,000
Share-based Compensation Arrangement by Share-based Payment Award, Discount	hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscount	125,000
Share-based Compensation Arrangement by Share-based Payment Award, Discount	hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscount	$ 158,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Unvested, Weighted Average Remaining Contractual Term	hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm	8 years 4 months 24 days
Accrued Professional Fees Consulting And Other Services	hrmy_AccruedProfessionalFeesConsultingAndOtherServices	$ 5,240,000
Accrued Professional Fees Consulting And Other Services	hrmy_AccruedProfessionalFeesConsultingAndOtherServices	3,047,000
Research and Development Expense Excluding Share-based Compensation and In Process Research and Development Expense	hrmy_ResearchAndDevelopmentExpenseExcludingShareBasedCompensationAndInProcessResearchAndDevelopmentExpense	33,046,000
Research and Development Expense Excluding Share-based Compensation and In Process Research and Development Expense	hrmy_ResearchAndDevelopmentExpenseExcludingShareBasedCompensationAndInProcessResearchAndDevelopmentExpense	19,305,000
Research and Development Expense Excluding Share-based Compensation and In Process Research and Development Expense	hrmy_ResearchAndDevelopmentExpenseExcludingShareBasedCompensationAndInProcessResearchAndDevelopmentExpense	65,284,000
Research and Development Expense Excluding Share-based Compensation and In Process Research and Development Expense	hrmy_ResearchAndDevelopmentExpenseExcludingShareBasedCompensationAndInProcessResearchAndDevelopmentExpense	40,123,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Unvested, Intrinsic Value	hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue	$ 4,888,000
Number Of Major Customers	hrmy_NumberOfMajorCustomers	3
Number Of Major Customers	hrmy_NumberOfMajorCustomers	3
Number Of Major Customers	hrmy_NumberOfMajorCustomers	3
Number Of Major Customers	hrmy_NumberOfMajorCustomers	3
Stock Appreciation Rights Market Adjustment	hrmy_StockAppreciationRightsMarketAdjustment	$ (110,000)
Stock Appreciation Rights Market Adjustment	hrmy_StockAppreciationRightsMarketAdjustment	$ (85,000)
Concentrations of Risk, Number Of Financial Institutions	hrmy_ConcentrationsOfRiskNumberOfFinancialInstitutions	5
Common Stock, Number of Votes per Share	hrmy_CommonStockNumberOfVotesPerShare	1
Selling and Marketing Expense Excluding Share-based Compensation	hrmy_SellingAndMarketingExpenseExcludingShareBasedCompensation	$ 28,421,000
Selling and Marketing Expense Excluding Share-based Compensation	hrmy_SellingAndMarketingExpenseExcludingShareBasedCompensation	26,407,000
Selling and Marketing Expense Excluding Share-based Compensation	hrmy_SellingAndMarketingExpenseExcludingShareBasedCompensation	56,388,000
Selling and Marketing Expense Excluding Share-based Compensation	hrmy_SellingAndMarketingExpenseExcludingShareBasedCompensation	51,646,000
In-Process Research and Development Acquired	hrmy_InProcessResearchAndDevelopmentAcquired	15,000,000
In-Process Research and Development Acquired	hrmy_InProcessResearchAndDevelopmentAcquired	42,595,000
In-Process Research and Development Acquired	hrmy_InProcessResearchAndDevelopmentAcquired	17,095,000
Adjustment for Amortization of Debt Issuance Costs	hrmy_AdjustmentForAmortizationOfDebtIssuanceCosts	329,000
Adjustment for Amortization of Debt Issuance Costs	hrmy_AdjustmentForAmortizationOfDebtIssuanceCosts	356,000
Share Based Compensation Arrangement by Share Based Payment Award Non Option Equity Instruments Outstanding Intrinsic Value	hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue	$ 610,000
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable	hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable	41,382
Number Of Approved Commercial Products	hrmy_NumberOfApprovedCommercialProducts	1
Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing	hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing	$ 1,655,000
Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing	hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing	$ 1,984,000
Number Of Operating Leases	hrmy_NumberOfOperatingLeases	2
Accrued Rebates And Other Sales Deductions Current	hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent	$ 61,129,000
Accrued Rebates And Other Sales Deductions Current	hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent	$ 50,542,000
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Remaining Contractual Terms	hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerms	3 years 9 months 18 days
Asset Acquisition, Upfront Consideration Paid	hrmy_AssetAcquisitionUpfrontConsiderationPaid	$ 35,000,000
Share Based Compensation Arrangement By Share Based Payment Award, Non Option Equity Instrument Exercisable Intrinsic Value	hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercisableIntrinsicValue	$ 597,000

Print Document
Details LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS (Details) LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS - CiRC Agreement (Details) Uncategorized Uncategorized Items - hrmy-20250630x10q_htm.xml All Reports

LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS - CiRC Agreement (Details) $ in Thousands	1 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2025 USD ($) item	Jun. 30, 2025 USD ($)	Jun. 30, 2025 USD ($)	Dec. 31, 2024 USD ($)
License Agreements and Asset Purchase Agreements
Number of developmental candidates \| item	2
Payment of upfront license fee		$ 15,000	$ 15,000	$ 25,500
Additional milestone payments due upon achievement of research milestones	$ 2,000	2,000	2,000
Exercise fee payable upon exercise of each option	8,000	8,000	8,000
Aggregate exercise fee payable upon exercise	$ 16,000	$ 16,000	$ 16,000